Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05991167 · ClinicalTrials.gov registry record

EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")

A clinical trial of ADHD, sponsored by Akili Interactive Labs.

Active
Registry status
150
Enrollment target
1
Study location

NCT05991167 is a study of ADHD that is active but no longer recruiting, run by Akili Interactive Labs. The registered enrollment target is 150 participants, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05991167, a study of ADHD, is active but no longer recruiting, sponsored by Akili Interactive Labs.

ACTIVE NOT RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

Conditions Studied

Interventions

  • DEVICE EndeavorRx

Study Locations (1)

Massachusetts

  • Akili Interactive Labs, Inc. - Boston

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-06-01
Est. Completion 2025-12-31

Sponsor

Akili Interactive Labs

13 total trials

What the Registry Record Tells You About NCT05991167

The ClinicalTrials.gov registry entry for NCT05991167 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 75 other ADHD trials with a reported enrollment target (20% lower). The listed sponsor is Akili Interactive Labs, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which EndeavorRx is the first listed.

NCT05991167 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05991167 about?

NCT05991167 is a clinical study titled "EndeavorRx® Prospective Product Registry ("Expedition EndeavorRx")". The EndeavorRx Prospective Product Registry aims to collect real world data from participants receiving the digital therapeutic, EndeavorRx, under conditions of routine clinical practice.

What is the current status of trial NCT05991167?

This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2022-06-01. Estimated completion is 2025-12-31.

What conditions does trial NCT05991167 study?

This clinical trial studies the following conditions: ADHD.

What interventions are being tested in trial NCT05991167?

The interventions under investigation include: EndeavorRx (DEVICE).

Who is sponsoring clinical trial NCT05991167?

This trial is sponsored by Akili Interactive Labs, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05991167 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for ADHD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.